Biomarkers for Predicting Clinical Response to Immunosuppressive Therapy in Aplastic Anemia

Overview

Journal Int J Hematol

Specialty Hematology

Date 2016 Apr 20

PMID 27091471

Citations 9

Authors

Atsushi Narita

Seiji Kojima

Affiliations

Soon will be listed here.

Abstract

The decision to select hematopoietic stem cell transplantation (HSCT) or immunosuppressive therapy (IST) as initial therapy in acquired aplastic anemia (AA) is currently based on patient age and the availability of a human leukocyte antigen (HLA)-matched donor. Although IST is a promising treatment option, the ability to predict its long-term outcomes remains poor due to refractoriness, relapses, and the risk of clonal evolution. Several predictive biomarkers for response to IST have been posited, including age, gender, pre-treatment blood cell counts, cytokines, gene mutations, paroxysmal nocturnal hemoglobinuria (PNH), and telomere length (TL). While previous studies have provided substantial biological insights into the utility of IST, the prognostic power of the reported biomarkers is currently insufficient to contribute to clinical decision making. Recently, a large retrospective analysis proposed the combination of minor PNH clones and TL as an efficient predictor of IST response. Identification of a reliable predictor would provide a useful tool for determining the most appropriate treatment choice for AA patients, including up-front HSCT from HLA-matched unrelated donor. The present review summarizes studies evaluating the utility of biomarkers in predicting the clinical response to IST of patients with AA, and provides a baseline for prospective studies aimed at validating previously reported biomarkers.

Citing Articles

Modified Delphi panel consensus recommendations for management of severe aplastic anemia.

Babushok D, DeZern A, de Castro C, Rogers Z, Beenhouwer D, Broder M Blood Adv. 2024; 8(15):3946-3960.

PMID: 38669341 PMC: 11331724. DOI: 10.1182/bloodadvances.2023011642.

Hematopoietic stem cell transplantation of aplastic anemia by relative with mutations and normal telomere length: A case report.

Yan J, Jin T, Wang L World J Clin Cases. 2023; 11(29):7200-7206.

PMID: 37946752 PMC: 10631418. DOI: 10.12998/wjcc.v11.i29.7200.

Idiopathic Aplastic anemia: Indian Perspective.

Dolai T, Jain M, Mahapatra M Indian J Hematol Blood Transfus. 2023; 39(3):357-370.

PMID: 37304471 PMC: 10247658. DOI: 10.1007/s12288-022-01592-4.

Anti-COX-2 autoantibody is a novel biomarker of immune aplastic anemia.

Kelkka T, Tyster M, Lundgren S, Feng X, Kerr C, Hosokawa K Leukemia. 2022; 36(9):2317-2327.

PMID: 35927326 PMC: 9417997. DOI: 10.1038/s41375-022-01654-6.

Response to Immunosuppressive Therapy in Acquired Aplastic Anaemia: Experience of a Tertiary Care Centre from Eastern India.

Dutta B, Dolai T, Mandal P, Baul S, De R, Senthil K Indian J Hematol Blood Transfus. 2021; 37(2):197-203.

PMID: 33867724 PMC: 8012467. DOI: 10.1007/s12288-019-01158-x.

References

Scheinberg P, Wu C, Nunez O, Young N . Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. J Pediatr. 2008; 153(6):814-9. PMC: 3971527. DOI: 10.1016/j.jpeds.2008.06.004. View

Dufour C, Pillon M, Socie G, Rovo A, Carraro E, Bacigalupo A . Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. Br J Haematol. 2015; 169(4):565-73. DOI: 10.1111/bjh.13297. View

Kulagin A, Lisukov I, Ivanova M, Golubovskaya I, Kruchkova I, Bondarenko S . Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: results of two-centre prospective study. Br J Haematol. 2013; 164(4):546-54. DOI: 10.1111/bjh.12661. View

Wang H, Chuhjo T, Yamazaki H, Shiobara S, Teramura M, Mizoguchi H . Relative increase of granulocytes with a paroxysmal nocturnal haemoglobinuria phenotype in aplastic anaemia patients: the high prevalence at diagnosis. Eur J Haematol. 2001; 66(3):200-5. DOI: 10.1034/j.1600-0609.2001.00376.x. View

Yoshida N, Yagasaki H, Takahashi Y, Yamamoto T, Liang J, Wang Y . Clinical impact of HLA-DR15, a minor population of paroxysmal nocturnal haemoglobinuria-type cells, and an aplastic anaemia-associated autoantibody in children with acquired aplastic anaemia. Br J Haematol. 2008; 142(3):427-35. DOI: 10.1111/j.1365-2141.2008.07182.x. View

Tutelman P, Aubert G, Milner R, Dalal B, Schultz K, Deyell R . Paroxysmal nocturnal haemoglobinuria phenotype cells and leucocyte subset telomere length in childhood acquired aplastic anaemia. Br J Haematol. 2013; 164(5):717-21. DOI: 10.1111/bjh.12656. View

Narita A, Muramatsu H, Sekiya Y, Okuno Y, Sakaguchi H, Nishio N . Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia. Haematologica. 2015; 100(12):1546-52. PMC: 4666330. DOI: 10.3324/haematol.2015.132530. View

Viollier R, Socie G, Tichelli A, Bacigalupo A, Korthof E, Marsh J . Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant. 2007; 41(1):45-50. DOI: 10.1038/sj.bmt.1705894. View

Bacigalupo A, Oneto R, Bruno B, Socie G, Passweg J, Locasciulli A . Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Report of the European Group for Blood and Marrow transplantation. On behalf of the Working Party on Severe Aplastic Anemia of the European Group for.... Acta Haematol. 2000; 103(1):19-25. DOI: 10.1159/000041000. View

10.

Afable 2nd M, Shaik M, Sugimoto Y, Elson P, Clemente M, Makishima H . Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica. 2011; 96(9):1269-75. PMC: 3166096. DOI: 10.3324/haematol.2011.042622. View

11.

Yoshida N, Yagasaki H, Hama A, Takahashi Y, Kosaka Y, Kobayashi R . Predicting response to immunosuppressive therapy in childhood aplastic anemia. Haematologica. 2011; 96(5):771-4. PMC: 3084926. DOI: 10.3324/haematol.2010.032805. View

12.

Marchio C, Dowsett M, Reis-Filho J . Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box. BMC Med. 2011; 9:41. PMC: 3102629. DOI: 10.1186/1741-7015-9-41. View

13.

Sugimori C, Chuhjo T, Feng X, Yamazaki H, Takami A, Teramura M . Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2005; 107(4):1308-14. DOI: 10.1182/blood-2005-06-2485. View

14.

Dufour C, Veys P, Carraro E, Bhatnagar N, Pillon M, Wynn R . Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia.... Br J Haematol. 2015; 171(4):585-94. DOI: 10.1111/bjh.13614. View

15.

Nissen C, Gratwohl A, Tichelli A, Stebler C, Wursch A, Moser Y . Gender and response to antilymphocyte globulin (ALG) for severe aplastic anaemia. Br J Haematol. 1993; 83(2):319-25. DOI: 10.1111/j.1365-2141.1993.tb08288.x. View

16.

Miano M, Dufour C . The diagnosis and treatment of aplastic anemia: a review. Int J Hematol. 2015; 101(6):527-35. DOI: 10.1007/s12185-015-1787-z. View

17.

Scheinberg P . Prognostic value of telomere attrition in patients with aplastic anemia. Int J Hematol. 2013; 97(5):553-7. DOI: 10.1007/s12185-013-1332-x. View

18.

Kojima S, Hibi S, Kosaka Y, Yamamoto M, Tsuchida M, Mugishima H . Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000; 96(6):2049-54. View

19.

Miyata T, Yamada N, Iida Y, Nishimura J, Takeda J, Kitani T . Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1994; 330(4):249-55. DOI: 10.1056/NEJM199401273300404. View

20.

Fuhrer M, Rampf U, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G . Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood. 2005; 106(6):2102-4. DOI: 10.1182/blood-2005-03-0874. View